Company Coverage
TA: Link Real Estate Investment Trust (0823 HK) / Sino Biopharmaceutical (1177 HK)
Analyst


Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at the following link: https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
Our latest research

13 Nov 2026
LINK REIT (823 HK): 1HFY27: DPU Slightly Ahead; Solid Strategy Execution To Sharpen Focus On Retail In Asia Pacific

13 Nov 2026
Edge Medical (2675 HK): Price War Clouds 2026 Revenue; Seeking Strategic Shift Toward High-end Market Via New Product Launches
12 Nov 2026
